Developed-country multinationals (DMNEs) have increasingly engaged in the practice of offshoring innovation to emerging countries. In this article, we leverage and extend the institution-based view to further our understanding of this phenomenon. Specifically, we examine the differential effects...

As the U.S. loses its monopoly in high technology, policymakers are calling for increases in the number of science and technology graduates and in R&D investment. We believe these proposals fail to recognize what is distinctive about the emerging global economy. Our studies of engineering in...

Effective promoting national innovative capacity performance tends to be a critical policy for a country. This study examines network contagion effects on international diffusion of embodied and disembodied technology by two different social network models: cohesion models, which are based on...

What is the role of transport improvements in globalization? We argue that the nineteenth century is the ideal testing ground for this question: freight rates fell on average by 50% while global trade increased 400% from 1870 to 1913. We estimate the first indices of bilateral freight rates for...

This article considers a gap between patent law and competition law that is being profitably exploited by "patent trolls", firms whose business is the acquisition and assertion of patents against parties who are already using the patented technology. First, we frame the discussion by considering...

The Analysis puts the focus on links between EU-integration and globalization. The EU is active in the process of globalization, particularly through the EU single market and EU eastern enlargement. As regards major other impulses for economic globalization the focus is on technological progress...

This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process. Lack of competition in the drug approval process has led to exceedingly high drug development costs....

Do policies that alter the allocation of human capital across individuals affect the innovation capacity of an economy? To answer this question, I extend Romer's (1990) growth model to allow for individual heterogeneity. I find that the value of an invention rises with equality. If skills and...

In this paper, we argue that lower prices for pharmaceuticals can be achieved by fostering a new type of competition in the pharmaceutical industry. Lower drug development costs, and hence prices, can be brought about by abolishing national drug administrations and replacing them with private...

We develop measures for technology decoupling and dependence between the U.S. and China based on combined patent data. The first two decades of the century witnessed a steady increase in technology integration (or less decoupling), but China’s dependence on the U.S. increased (decreased)...